Hiking the Appalachian Trail, Steve Weisel thought little of the blisters on his feet until he discovered they were infected with life-threatening methicillin-resistant Staphylococcus aureus (MRSA) -- an increasingly common "superbug" that does not respond to first-line antibiotics. Mr. Weisel's story demonstrates the urgent need for new and innovative therapies to treat this growing threat.
Sixty-two years old and very active, Steve Weisel was about 300 miles into a long trek across the Appalachian Trail when blisters on his feet became too painful to bear. He stopped the hike early and returned to his home in Virginia.
Over the next week, Mr. Weisel’s blisters did not heal and he developed a fever. When his temperature spiked, he checked into the infectious diseases clinic at the National Naval Medical Center in Maryland. The blisters he thought were harmless turned out to be infected with the dangerous superbug MRSA, which had also spread to his lungs. As a result, he had developed pneumonia and a collection of pus-filled abscesses between his lungs and chest wall.
To thwart the MRSA infection that had permeated his lungs, Mr. Weisel required aggressive medical intervention during his 18-day hospital stay. He underwent a number of major surgical procedures to drain the abscesses, and he was treated with six different antibiotics. He left with home-administered intravenous vancomycin—a medication that produced a rash so large and unpleasant that he had to be switched to yet another drug.
Though patients typically contract MRSA in a health care setting, rates of community-acquired MRSA have grown rapidly over the past 10 yearsand are not showing signs of declining.1
Mr. Weisel’s battle lasted for well over a month and required a lengthy hospitalization and treatment followed by an arduous rehabilitation.
Fortunately, he made a full recovery and completed his 2,000-mile hike. His story illustrates the growing need for new antibiotics that can fight
infections quickly and effectively.
Nearly a year after the enactment of the Generating Antibiotic Incentives Now Act, the U.S. Food and Drug Administration has released draft guidance for industry on developing antibacterial therapies for patients with unmet medical needs.
More infoAs multidrug-resistant infections have grown more prevalent, few new antibiotics are reaching the market. This is attributed, in part, to the economic and regulatory challenges associated with their development. Recently, stakeholders have endorsed a novel regulatory pathway to approve these lifesaving drugs for use in limited patient populations — namely those at highest risk and with few or no other options.
More info"As a nation, we need to exercise greater care with our use of antibiotics, in both humans and animals, so that these medications remain effective in treating serious bacterial infections."
More infoCopyright(c) 1996-2012 The Pew Charitable Trusts. All Rights Reserved.
[+] Feedback PHG.PRODUCTION.1.20130703.1022 (PEWSUWVMWAPP01)
